Guided Therapeutics Inc (OTCBB:GTHP) has been making quite a lot of progress with respect to its LuViva cervical scan systems. The company has received additional orders for the system from Bangladesh and Turkey. Both countries seem to realize the importance of this technology for use in the detection of cervical cancer. Bangladesh has awarded GTHP contracts for four additional LuViva systems, doubling the number of systems the country has bought from GTHP. Turkey on the other hand has made a significantly larger order of 100-LuViva systems.
Turkey, unlike Bangladesh, has bought the additional 100 systems through its ministry of health and is expected to use them not only in hospitals, but in medical schools and diagnostic centers as well. GTHP is expected to start filling this order from October. The sales in Bangladesh have been made to a number of government agencies, but are expected to be used in hospitals only.
LuViva has been gaining significant attention around the world in developed and un-developed countries alike. The system is thought to be capable of delivering the best cervical cancer screening to women. The third-world countries are taking a special interest in the program, since the diagnosis is much cheaper than traditional methods. Additionally, the accuracy of the LuViva system stands unrivalled, for now, making the test highly in demand.
The Turkish government even went on to handpick professionals to put LuViva through clinical trials and report on its efficiency. The results of these trials were later sent to the health ministry and made public in professional meetings as well. Bangladesh, in particular, was the largest market for the company, since cervical cancer is the most common type of cancer amongst women in the country. The company would hope that the growing need for this vital test in the country leads to further orders for the innovative system.
Guided Therapeutics Inc (OTCBB:GTHP) lost 14.29% and is now trading at $0.120, after trading 171,200 shares and is now trading at $0.120.